Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
- PMID: 10341273
- DOI: 10.1056/NEJM199905273402102
Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy
Abstract
Background and methods: Although potent antiretroviral therapy can control infection with human immunodeficiency virus type 1 (HIV-1), a long-lived reservoir of infectious virus persists in CD4+ T cells. We investigated this viral reservoir by measuring the levels of cell-associated viral DNA and messenger RNA (mRNA) that are essential for HIV-1 replication. Approximately every 6 months, we obtained samples of peripheral-blood mononuclear cells from five men with long-standing HIV-1 infection who had had undetectable levels of plasma HIV-1 RNA for 20 months or more during treatment with potent antiretroviral drugs.
Results: Before treatment, plasma levels of HIV-1 RNA correlated with the levels of cell-associated unintegrated HIV-1 DNA and unspliced viral mRNA. After treatment, plasma levels of HIV-1 RNA fell by more than 2.7 log to undetectable levels. The decrease in cell-associated integrated and unintegrated HIV-1 DNA and mRNA occurred in two phases. The first phase occurred during the initial 500 days of treatment and was characterized by substantial decreases in the levels of DNA and mRNA, but not to undetectable levels. The concentrations of cell-associated unintegrated viral DNA, integrated proviral DNA, and unspliced viral mRNA decreased by 1.25 to 1.46 log. The second phase occurred during the subsequent 300 days or more of treatment and was characterized by a plateau in the levels of HIV-1 DNA and unspliced mRNA. After an initial rapid decline, the ratio of unspliced to multiply spliced viral mRNA (a measure of active viral transcription) stabilized and remained greater than zero at each measurement.
Conclusions: Despite treatment with potent antiretroviral drugs and the suppression of plasma HIV-1 RNA to undetectable levels for 20 months or more, HIV-1 transcription persists in peripheral-blood mononuclear cells. Unless the quasi-steady state levels of HIV DNA and mRNA eventually disappear with longer periods of therapy, these findings suggest that HIV-1 infection cannot be eradicated with current treatments.
Comment in
-
Residual HIV-1 disease in the era of highly active antiretroviral therapy.N Engl J Med. 1999 May 27;340(21):1672-4. doi: 10.1056/NEJM199905273402110. N Engl J Med. 1999. PMID: 10341281 No abstract available.
Similar articles
-
Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.N Engl J Med. 1999 May 27;340(21):1605-13. doi: 10.1056/NEJM199905273402101. N Engl J Med. 1999. PMID: 10341272 Clinical Trial.
-
Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy.N Engl J Med. 1998 Dec 17;339(25):1803-9. doi: 10.1056/NEJM199812173392502. N Engl J Med. 1998. PMID: 9854115
-
Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.N Engl J Med. 2001 Feb 15;344(7):472-80. doi: 10.1056/NEJM200102153440702. N Engl J Med. 2001. PMID: 11172188 Clinical Trial.
-
Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review.
-
Meaning of DNA detection during the follow-up of HIV-1 infected patients: a brief review.New Microbiol. 2006 Apr;29(2):81-8. New Microbiol. 2006. PMID: 16841548 Review.
Cited by
-
Increased cardiovascular disease risk in the HIV-positive population on ART: potential role of HIV-Nef and Tat.Cardiovasc Pathol. 2015 Sep-Oct;24(5):279-82. doi: 10.1016/j.carpath.2015.07.001. Epub 2015 Jul 9. Cardiovasc Pathol. 2015. PMID: 26233281 Free PMC article. Review.
-
Detection of replication-competent human immunodeficiency virus type 1 (HIV-1) in cultures from patients with levels of HIV-1 RNA in plasma suppressed to less than 500 or 50 copies per milliliter.J Clin Microbiol. 2002 Jun;40(6):2089-94. doi: 10.1128/JCM.40.6.2089-2094.2002. J Clin Microbiol. 2002. PMID: 12037070 Free PMC article. Clinical Trial.
-
Latent reservoirs of HIV: obstacles to the eradication of virus.Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):10958-61. doi: 10.1073/pnas.96.20.10958. Proc Natl Acad Sci U S A. 1999. PMID: 10500107 Free PMC article.
-
Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells.J Virol. 2006 Aug;80(15):7645-57. doi: 10.1128/JVI.00206-06. J Virol. 2006. PMID: 16840343 Free PMC article.
-
Antigen-driven CD4+ T cell and HIV-1 dynamics: residual viral replication under highly active antiretroviral therapy.Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15167-72. doi: 10.1073/pnas.96.26.15167. Proc Natl Acad Sci U S A. 1999. PMID: 10611356 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials